The effect of inoculum size on selection of in vitro resistance to vancomycin, daptomycin, and linezolid in methicillin-resistant staphylococcus aureus

Microbial Drug Resistance

Volumn 20, Issue 6, 2014, Pages 539-543

  Rio Marques, Laura ^a,b   Hartke, Axel ^c   Bizzini, Alain ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITÉ DE CAEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; LINEZOLID; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; METICILLIN; OXAZOLIDINONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; EFFECT SIZE; IN VITRO STUDY; INOCULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PROCEDURES; STAPHYLOCOCCAL INFECTIONS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; METHICILLIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84915788479     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2014.0059     Document Type: Article

References (30)

1. Bayer, A.S., T. Schneider, and H.G. Sahl. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann. N. Y. Acad. Sci. 1277:139-158.
2. Besier, S., A. Ludwig, J. Zander, V. Brade, and T.A. Wichelhaus. 2008. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and crossresistances. Antimicrob. Agents Chemother. 52:1570-1572.
3. Brook, I. 1989. Inoculumeffect.Rev. Infect.Dis. 11:361-368.
4. Clinical and Laboratory Institute. 2009. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard-Eight edition, CLSI Document, Wayne, Pennsilvania: Clinical and Laboratory Standards Institute, M0-A08.
5. Davis, S.L., P.S. McKinnon, L.M. Hall, G. Delgado, Jr., W. Rose, R.F. Wilson, and M.J. Rybak. 2007. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy 27:1611-1618.
6. Dortet, L., N. Anguel, N. Fortineau, C. Richard, and P. Nordmann. 2013. In vivo acquired daptomycin resistance during treatment of methicillin-resistant Staphylococcus aureus endocarditis. Int. J. Infect. Dis. 17:e1076-e1077.
7. Entenza, J.M., M. Giddey, J. Vouillamoz, and P. Moreillon. 2010. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin. Int. J. Antimicrob. Agents 35:451-456.
8. Falagas, M.E., I.I. Siempos, and K.Z. Vardakas. 2008. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect. Dis. 8:53-66.
9. Fischer, A., S.J. Yang, A.S. Bayer, A.R. Vaezzadeh, S. Herzig, L. Stenz, M. Girard, G. Sakoulas, A. Scherl, M.R. Yeaman, et al. 2011. Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. J. Antimicrob. Chemother. 66:1696-1711.
10. Fowler, V.G., Jr., H.W. Boucher, G.R. Corey, E. Abrutyn, A.W. Karchmer, M.E. Rupp, D.P. Levine, H.F. Chambers, F.P. Tally, G.A. Vigliani, et al. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
11. Gasch, O., M. Camoez, M.A. Dominguez, B. Padilla, V. Pintado, B. Almirante, C. Martin, F. Lopez-Medrano, E.R. de Gopegui, J.R. Blanco, et al. Emergence of resistance to daptomycin in a cohort of patients with methicillinresistant Staphylococcus aureus persistent bacteraemia treated with daptomycin. J. Antimicrob. Chemother. 69: 568-571.
12. Herrmann, D.J., W.J. Peppard, N.A. Ledeboer, M.L. Theesfeld, J.A. Weigelt, and B.J. Buechel. 2008. Linezolid for the treatment of drug-resistant infections. Expert Rev. Anti Infect. Ther. 6:825-848.
13. Levine, D.P. 2006. Vancomycin: a history. Clin. Infect. Dis. 42 Suppl 1:S5-S12.
14. Matsuo, M., L. Cui, J. Kim, and K. Hiramatsu. 2013. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3. Antimicrob. Agents Chemother. 57:5843-5853.
15. Moellering, R.C., Jr. 2006. Vancomycin: a 50-year reassessment. Clin. Infect. Dis. 42 Suppl 1:S3-S4.
16. Pootoolal, J., J. Neu, and G.D. Wright. 2002. Glycopeptide antibiotic resistance. Annu. Rev. Pharmacol. Toxicol. 42:381-408.
17. Quiles-Melero, I., R. Gomez-Gil, M.P. Romero-Gomez, A.M. Sanchez-Diaz, M. de Pablos, J. Garcia-Rodriguez, A. Gutierrez, and J. Mingorance. 2013. Mechanisms of linezolid resistance among Staphylococci in a tertiary hospital. J. Clin. Microbiol. 51:998-1001.
18. Sabath, L.D., C. Garner, C. Wilcox, and M. Finland. 1975. Effect of inoculum and of beta-lactamase on the antistaphylococcal activity of thirteen penicillins and cephalosporins. Antimicrob. Agents Chemother. 8:344-349.
19. Sharma, M., K. Riederer, P. Chase, and R. Khatib. 2008. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur. J. Clin. Microbiol. Infect. Dis. 27:433-437.
20. Silverman, J.A., N. Oliver, T. Andrew, and T. Li. 2001. Resistance studies with daptomycin. Antimicrob. Agents Chemother. 45:1799-1802.
21. Smith, T.L., M.L. Pearson, K.R. Wilcox, C. Cruz, M.V. Lancaster, B. Robinson-Dunn, F.C. Tenover, M.J. Zervos, J.D. Band, E. White, et al. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N. Engl. J. Med. 340:493-501.
22. Soriano, F. 1992. Optimal dosage of beta-lactam antibiotics: time above the MIC and inoculum effect. J. Antimicrob. Chemother. 30:566-569.
23. Soriano, F., C. Ponte, M. Santamaria, and M. Jimenez-Arriero. 1990. Relevance of the inoculum effect of antibiotics in the outcome of experimental infections caused by Escherichia coli. J. Antimicrob. Chemother. 25:621-627.
24. Steenbergen, J.N., J. Alder, G.M. Thorne, and F.P. Tally. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 55:283-288.
25. Tally, F.P., and M.F. DeBruin. 2000. Development of daptomycin for gram-positive infections. J. Antimicrob. Chemother. 46:523-526.
26. Tsiodras, S., H.S. Gold, G. Sakoulas, G.M. Eliopoulos, C. Wennersten, L. Venkataraman, R.C. Moellering, and M.J. Ferraro. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358:207-208.
27. Udekwu, K.I., N. Parrish, P. Ankomah, F. Baquero, and B.R. Levin. 2009. Functional relationship between bacterial cell density and the efficacy of antibiotics. J. Antimicrob. Chemother. 63:745-757.
28. van Hal, S.J., D.L. Paterson, and I.B. Gosbell. 2011. Emergence of daptomycin resistance following vancomycinunresponsive Staphylococcus aureus bacteraemia in a daptomycin-naive patient-a review of the literature. Eur. J. Clin. Microbiol. Infect. Dis. 30:603-610.
29. Vilhena, C., and A. Bettencourt. 2012. Daptomycin: a review of properties, clinical use, drug delivery and resistance. Mini Rev. Med. Chem. 12:202-209.
30. Wise, R., J.M. Andrews, F.J. Boswell, and J.P. Ashby. 1998. The in vitro activity of linezolid (U-100766) and tentative breakpoints. J. Antimicrob. Chemother. 42:721-728.